The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 26, 2017
Filed:
Feb. 23, 2015
Applicant:
Amira Pharmaceuticals, Inc., Princeton, NJ (US);
Inventors:
Jeffrey Roger Roppe, Temecula, CA (US);
Timothy Andrew Parr, La Mesa, CA (US);
Nicholas Simon Stock, Encinitas, CA (US);
Deborah Volkots, New York, NY (US);
John Howard Hutchinson, San Diego, CA (US);
Assignee:
AMIRA PHARMACEUTICALS, INC., Princeton, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 209/36 (2006.01); C07D 209/30 (2006.01); A61K 31/404 (2006.01); C07D 209/08 (2006.01); C07D 209/12 (2006.01); C07D 209/32 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 403/04 (2006.01); C07D 409/04 (2006.01); C07D 417/04 (2006.01); C07D 401/10 (2006.01); C07D 403/12 (2006.01); C07F 5/02 (2006.01); A61K 31/41 (2006.01); A61K 31/4155 (2006.01); A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/69 (2006.01);
U.S. Cl.
CPC ...
A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/4155 (2013.01); A61K 31/427 (2013.01); A61K 31/4245 (2013.01); A61K 31/4439 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/69 (2013.01); C07D 209/08 (2013.01); C07D 209/12 (2013.01); C07D 209/30 (2013.01); C07D 209/32 (2013.01); C07D 209/36 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 409/04 (2013.01); C07D 417/04 (2013.01); C07F 5/025 (2013.01);
Abstract
Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.